Wells Fargo Initiates Coverage On X4 Pharmaceuticals with Overweight Rating, Announces Price Target of $11

Benzinga Newsdesk www.benzinga.com Neutral 63.1%

Neg 0% Neu 63.1% Pos 0%

Wells Fargo analyst Derek Archila initiates coverage on X4 Pharmaceuticals (NASDAQ:XFOR) with a Overweight rating and announces Price Target of $11.